Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EC approval under the EMEA Accelerated Assessment Procedure.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians are enrolled in the Soliris Safety Registry, which is part of a special risk-management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide arra
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... , Sept. 19, 2014  The body of ... the publication of two papers this past week.  The ... Head and Neck Surgery , finds that withholding ... subjective measures of sleep disordered breathing, leading the paper,s ... in obstructive sleep apnea severity and improvement of quality ...
(Date:9/19/2014)... Sept. 19, 2014  CytRx Corporation (Nasdaq: ... in oncology, today announced that David J. Haen ... 2014 NewsMakers in the Biotech Industry Conference on Friday, September ... conference will take place at the Millennium Broadway Hotel ... A live and archived webcast of the presentation ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... of Atlanta is the first hospital in Georgia to ... an advanced radiosurgery device specifically designed to treat brain ... , A gentler alternative to traditional brain surgery, ... radiation beams to one or more targets in a ...
... , FRANKLIN, Mass., Oct. 1 Echo Therapeutics, Inc. ... company developing the needle-free Symphony(TM) tCGM System as a ... the Prelude(TM) SkinPrep System for transdermal drug delivery, announced ... Executive Officer, will present at the 4th Annual JMP ...
Cached Medicine Technology:Saint Joseph's Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion 2Saint Joseph's Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion 3Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 2
(Date:9/21/2014)... 2014 Top10BestSEOHosting.com, a leading review ... and GreenGeeks are the most recommended hosting suppliers ... high quality hosting products. , “Don’t waste ... we recommend two great hosting companies to you,” ... that iPage and GreenGeeks are the most recommended ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses and ... announced evening cocktail dresses . As a matter ... are very popular among worldwide customers. Now, all its ... to 65 percent off). , All UWDress.com’s employees ... outfits for the global clients. The company is famous ...
(Date:9/20/2014)... Weight Destroyer , a weight ... Michael Wren that has already helped tens of thousands ... conditions like high blood pressure, high cholesterol, and accelerated ... an investigative review. , “Weight Destroyer is totally ... by showing people what is truly effective when it ...
(Date:9/20/2014)... Atlanta, GA (PRWEB) September 20, 2014 ... September 20, 2014. The first poster looked at the ... per cardiac cycle for calculating diastolic function. In conjunction ... with end-stage renal disease and normal LVEF by echo ... high-dose stress protocol, and standard SPECT. Emory Toolbox ...
(Date:9/20/2014)... 20, 2014 Villa del Palmar at ... not experience any damage in relation to Hurricane Odile ... available. , Hurricane Odile struck Cabo San Lucas the ... and powerful surf conditions. Located on the east side ... Loreto experienced some heavy rain, but no damage whatsoever ...
Breaking Medicine News(10 mins):Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3
... counts soar when evergreens are brought indoors, researchers find , , ... live Christmas tree marks the beginning of the holiday season ... trigger weeks of suffering for some, a new study shows. ... a live Christmas tree rose to five times the normal ...
... LOS ANGELES, Nov. 16 Neutrogena(R), a worldwide ... cosmetics, announced today that actress Diane Lane has ... Ms. Lane is a captivating and inspiring ... beauty and daring spirit. In her new,role, she ...
... Allscripts, the leading,provider of clinical software, ... improve healthcare, on behalf of the National,ePrescribing ... for Medicare and Medicaid Services (CMS) proposal ... used by participants in the Medicare,prescription drug ...
... Directors and Reject ... Ramius, Opposition Slate, ... today mailed the following letter to all shareholders from,Lawrence Saper, ... the Company,s Annual Meeting of Shareholders scheduled for,Thursday, December 20, ...
... 16 Schering-Plough,Corporation (NYSE: SGP ) today ... U.S. Federal Trade Commission (FTC) regarding its,planned acquisition ... as,announced March 12, 2007. Organon BioSciences is ... Intervet, the animal health business. It also,includes Nobilon, ...
... Research &,Instrumentation, Inc. (CRi) announced today that their ... Mitalipov to successfully transfer,nuclear genetic material from somatic ... to generate cloned macaque embryos. In a soon ... Oregon National Primate,Research Center and the Oregon Stem ...
Cached Medicine News:Health News:Live Christmas Trees Can Trigger Mold Allergies 2Health News:Live Christmas Trees Can Trigger Mold Allergies 3Health News:Update: Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador 2Health News:National ePrescribing Patient Safety Initiative Supports Medicare Proposal to Adopt Additional Standards for ePrescribing 2Health News:National ePrescribing Patient Safety Initiative Supports Medicare Proposal to Adopt Additional Standards for ePrescribing 3Health News:National ePrescribing Patient Safety Initiative Supports Medicare Proposal to Adopt Additional Standards for ePrescribing 4Health News:National ePrescribing Patient Safety Initiative Supports Medicare Proposal to Adopt Additional Standards for ePrescribing 5Health News:Datascope Mails Letter to Shareholders 2Health News:Datascope Mails Letter to Shareholders 3Health News:Datascope Mails Letter to Shareholders 4Health News:Datascope Mails Letter to Shareholders 5Health News:Datascope Mails Letter to Shareholders 6Health News:Datascope Mails Letter to Shareholders 7Health News:Datascope Mails Letter to Shareholders 8Health News:Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V. 2Health News:Oosight Imaging System Enables a Breakthrough: The Viable Transfer of Genetic Material for Stem Cell Nuclear Reprogramming in Primates 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: